Market Cap
$4.2B
TNGX
Tango Therapeutics, Inc.
$23.24 ▼ -4.95%
Prev close $24.45Market cap$4.2B
ConsensusStrong Buy
12-mo target$45.18 (+94.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)42 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TNGX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
50 funds
Inst. Value
$3.9B
Inst. Activity
42 buys / 8 sells
Insider Activity
$0.00 buy / $7.0M sell
Insider Net $
-$7.0M
Social Sentiment
50° Neutral
SEC Reports
17
Press Releases
2
Price chart 30d +2.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: TNGX — 79.0% short (0.9M / 1.1M)
Short: 862,867 | Exempt: 411 | TRF Vol: 1,092,747 | Short Ratio: 79.0% | Off-exchange volume (dark p
Sep 22, 2026 Insider
Newcomb Jessica sold 700 shares
Principal Accounting Officer @ $22.80 ($16.0K)
Sep 22, 2026 Insider
Newcomb Jessica sold 5,100 shares
Principal Accounting Officer @ $23.97 ($122.2K)
Sep 22, 2026 Insider
Aug 11, 2026 SEC Newcomb Jessica sold 2,400 shares
Principal Accounting Officer @ $25.17 ($60.4K)
Tango Therapeutics upsized its at-the-market (ATM) equity offering program from $100M to $400M, terminating the prior $1
8-K — Impact 6/10
Tango Therapeutics reported Q2 2026 financial results, highlighting a net loss of $55.3M ($0.37/share) vs $38.9M ($0.35/
8-K — Impact 7/10
Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zer
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
12,438,444 shares ($388.8M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 12, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 17, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 15, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| Jun 29, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jun 26, 2026 | Jefferies | UPGRADE | Buy | 53% |
| Jun 11, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jun 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 9, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jun 8, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 9 | 2 | 0 | 0 | 89% | |
| Aug 1, 2026 | 8 | 9 | 2 | 0 | 0 | 89% | |
| Jul 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| Jun 1, 2026 | 6 | 8 | 4 | 0 | 0 | 78% | |
| May 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 7 | 8 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Price targets
Where 11 covering analysts think TNGX trades over the next 12 months.
$45.18 +94.4% upside Strong Buy
Current$23.24 Low$24.00 Median$40.00 High$69.00 11 analysts
$24.00$69.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
17 SEC filing reports analyzed · 5 bullish, 2 bearish, 2 mixed, 8 neutral · avg impact 4.5/10.Plus 2 press releases.
BEARISH8-K6/10
Tango Therapeutics upsized its at-the-market (ATM) equity offering program from $100M to $400M, term
Aug 11, 2026
BULLISH8-K7/10
Tango Therapeutics reported Q2 2026 financial results, highlighting a net loss of $55.3M ($0.37/shar
Aug 11, 2026
BULLISHPRESS-RELEASE7/10
Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss
Aug 11, 2026
BULLISHINST-CLUSTER6/10
A strong institutional accumulation cluster for Tango Therapeutics (TNGX) emerged in Q2 2026, with 1
Aug 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: TNGX — 79.0% short (0.9M / 1.1M)
Short: 862,867 | Exempt: 411 | TRF Vol: 1,092,747 | Short Ratio: 79.0% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: TNGX — 55.4% short (0.8M / 1.4M)
Short: 752,442 | Exempt: 3,300 | TRF Vol: 1,357,782 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: TNGX — 76.4% short (0.6M / 0.8M)
Short: 596,796 | Exempt: 800 | TRF Vol: 780,875 | Short Ratio: 76.4% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: TNGX — 74.0% short (1.3M / 1.7M)
Short: 1,271,700 | Exempt: 2 | TRF Vol: 1,719,545 | Short Ratio: 74.0% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: TNGX — 57.7% short (0.9M / 1.5M)
Short: 850,379 | Exempt: 0 | TRF Vol: 1,473,290 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.35 | $-0.42–$-0.30 | -370.1% | -1.6% | 2↑ 6↓ | $0.0B | 12 |
| Next Q | $-0.37 | $-0.46–$-0.31 | -28.6% | -1.5% | 2↑ 7↓ | $0.0B | 12 |
| Current FY | $-1.40 | $-1.57–$-1.17 | -60.5% | -1.1% | 0↑ 10↓ | $0.0B | 12 |
| Next FY | $-1.69 | $-2.23–$-1.24 | -20.7% | -3.5% | 3↑ 5↓ | $0.0B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.351 | — |
| 7d ago | $-0.351 | — |
| 30d ago | $-0.346 | -0.005 |
| 60d ago | $-0.330 | -0.021 |
| 90d ago | $-0.331 | -0.020 |
Institutional ownership
Which big funds own TNGX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.9B total value (123,608,742 shares) as of 2026-Q2. Top holders: NOMURA, RTW, BlackRock,. Net buying activity: 42 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| RTW INVESTMENTS, LP | 13,900,620 | $434.5M | 11.2% | — |
| BlackRock, Inc. | 12,438,444 | $388.8M | 10.1% | ADD +42.2% |
| FMR LLC | 12,333,339 | $385.5M | 10.0% | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 12,277,000 | $383.8M | 9.9% | ADD +35.0% |
| GOLDMAN SACHS GROUP INC | 9,980,620 | $312.0M | 8.1% | ADD +96.6% |
| STATE STREET CORP | 5,979,806 | $186.9M | 4.8% | ADD +28.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,957,348 | $186.2M | 4.8% | — |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,600,000 | $175.1M | 4.5% | TRIM -56.3% |
| Jupiter Topco LLC | 5,056,352 | $158.0M | 4.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 8,748,045 | 12,438,444 | +42.2% | $388.8M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | ADD | 9,097,411 | 12,277,000 | +35.0% | $383.8M |
| GOLDMAN SACHS GROUP INC | ADD | 5,076,392 | 9,980,620 | +96.6% | $312.0M |
| STATE STREET CORP | ADD | 4,651,894 | 5,979,806 | +28.5% | $186.9M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 12,809,485 | 5,600,000 | -56.3% | $175.1M |
| Woodline Partners LP | TRIM | 8,000,013 | 4,000,567 | -50.0% | $125.1M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 2,675,777 | 3,742,791 | +39.9% | $117.0M |
| Holocene Advisors, LP | TRIM | 3,932,603 | 2,410,939 | -38.7% | $75.4M |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 3,826,659 | 2,016,379 | -47.3% | $63.0M |
| Jefferies Financial Group Inc. | NEW | — | 2,010,534 | — | $62.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net -$7.0M — $0.00 bought, $7.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | SELL | 700 | $22.80 | $16.0K |
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | SELL | 5,100 | $23.97 | $122.2K |
| Sep 22, 2026 | Newcomb Jessica | Principal Accounting Officer | SELL | 2,400 | $25.17 | $60.4K |
| Sep 1, 2026 | Crystal Adam | President, R&D | EXERCISE | 27,000 | $5.20 | $140.4K |
| Sep 1, 2026 | Crystal Adam | President, R&D | SELL | 27,000 | $22.37 | $603.9K |
| Aug 3, 2026 | Crystal Adam | President, R&D | SELL | 21,733 | $27.35 | $594.4K |
| Aug 3, 2026 | Crystal Adam | President, R&D | SELL | 5,267 | $26.79 | $141.1K |
| Aug 3, 2026 | Crystal Adam | President, R&D | EXERCISE | 27,000 | $5.20 | $140.4K |
| Jul 1, 2026 | Crystal Adam | President, R&D | SELL | 19,629 | $29.34 | $576.0K |
| Jul 1, 2026 | Crystal Adam | President, R&D | EXERCISE | 27,000 | $5.20 | $140.4K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TNGX.
Shares short
41,872,812
Settlement Sep 15, 2026
Change vs prior
-1.8%
Semi-monthly cycle
Days to cover
18.8
At avg daily volume
Of shares outstanding
≈24.8%
Estimate — not % of float
All TNGX filing & press-release reports (19)
- 8-K reportAug 11, 2026
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportAug 11, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportAug 6, 2026
- 144 reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- 424B5 reportJun 10, 2026
- 144 reportJun 10, 2026
- PRESS-RELEASE reportJun 10, 2026
- 424B5 reportJun 8, 2026
- 8-K reportJun 8, 2026
- 8-K reportMay 8, 2026
- 3 reportApr 24, 2026
- DEFA14A reportApr 17, 2026
- 8-K reportApr 15, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026